---
title: "Changjiang Securities: Winner Medical has relatively good performance elasticity and still has valuation cost-effectiveness advantages"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/244832327.md"
description: "Changjiang Securities' research report points out that after the concentration of equity and optimization of management, Winner Medical is expected to see an increase in the growth rate of its consumer and medical businesses in the future. The 2024 equity incentive plan will further drive performance growth. Although the stock price fluctuated in 2022 due to the impact of infection protection products, both the consumer and medical businesses have shown an upward trend since the third quarter of 2024, with both valuation and stock price rising. Compared to new consumer companies, Winner Medical has superior growth potential and performance elasticity, providing a valuation cost-performance advantage"
datetime: "2025-06-17T06:19:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/244832327.md)
  - [en](https://longbridge.com/en/news/244832327.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/244832327.md)
generator: "portal-rs"
---

# Changjiang Securities: Winner Medical has relatively good performance elasticity and still has valuation cost-effectiveness advantages

Changjiang Securities research report points out that Winner Medical has concentrated equity, introduced industry talents to improve the management team after 2020, and will release high targets for equity incentives in 2024. Looking ahead, consumption in personal care β, event dividends, and leading advantages will see an upward shift in growth rates, and due to structural optimization, sold-out conditions & improved discount rates, and precise marketing investments, profit growth will be even better. In the medical sector, the burden of impairment from infection protection products and mergers and acquisitions has significantly decreased, enhancing the certainty of growth under the consolidation of regular business and raising the growth center. The fluctuations in stock price and valuation from the listing to early 2022 were mainly influenced by infection protection products, while after 2022, stable consumption and regular medical services became the pricing business. Since Q3 2024, the bottom cycle of consumption and medical services has been on the rise, with both valuation and stock price increasing. Currently, compared to some new consumption companies, its growth potential is not weak, performance elasticity is relatively good, and it still has a valuation cost-performance advantage

### Related Stocks

- [300888.CN](https://longbridge.com/en/quote/300888.CN.md)
- [000783.CN](https://longbridge.com/en/quote/000783.CN.md)

## Related News & Research

- [Anker announces its first over-the-counter hearing aids](https://longbridge.com/en/news/297876505.md)
- [CTT Pharmaceutical Holdings CEO Ryan Khouri acquires 3,000 common shares valued at $147](https://longbridge.com/en/news/297819057.md)
- [MLP Saglik’s MPARK Shares Supported by Liquidity Provider OYA](https://longbridge.com/en/news/297808420.md)
- [13:11 ETALWAYS BEST CARE FRANCHISEES EXPAND SENIOR CARE SERVICES ACROSS CENTRAL INDIANA](https://longbridge.com/en/news/298062677.md)
- [Virgin Atlantic ends British Airways grip on Team GB partnership](https://longbridge.com/en/news/298063597.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**